EP3930747A4 - Association d'immunothérapies pour le traitement du cancer - Google Patents

Association d'immunothérapies pour le traitement du cancer Download PDF

Info

Publication number
EP3930747A4
EP3930747A4 EP20763489.0A EP20763489A EP3930747A4 EP 3930747 A4 EP3930747 A4 EP 3930747A4 EP 20763489 A EP20763489 A EP 20763489A EP 3930747 A4 EP3930747 A4 EP 3930747A4
Authority
EP
European Patent Office
Prior art keywords
treating cancer
immunotherapeutic combination
immunotherapeutic
combination
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20763489.0A
Other languages
German (de)
English (en)
Other versions
EP3930747A1 (fr
Inventor
Jonathan Zalevsky
Agnete Brunsvik Fredriksen
Mads Axelsen
Karoline SCHJETNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nykode Therapeutics ASA
Nektar Therapeutics
Original Assignee
Nykode Therapeutics ASA
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA, Nektar Therapeutics filed Critical Nykode Therapeutics ASA
Publication of EP3930747A1 publication Critical patent/EP3930747A1/fr
Publication of EP3930747A4 publication Critical patent/EP3930747A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20763489.0A 2019-02-27 2020-02-27 Association d'immunothérapies pour le traitement du cancer Withdrawn EP3930747A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962811459P 2019-02-27 2019-02-27
US201962825487P 2019-03-28 2019-03-28
US201962838180P 2019-04-24 2019-04-24
US201962881832P 2019-08-01 2019-08-01
PCT/US2020/020224 WO2020176797A1 (fr) 2019-02-27 2020-02-27 Association d'immunothérapies pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP3930747A1 EP3930747A1 (fr) 2022-01-05
EP3930747A4 true EP3930747A4 (fr) 2023-04-05

Family

ID=72238533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20763489.0A Withdrawn EP3930747A4 (fr) 2019-02-27 2020-02-27 Association d'immunothérapies pour le traitement du cancer

Country Status (4)

Country Link
EP (1) EP3930747A4 (fr)
JP (1) JP2022521792A (fr)
CN (1) CN113631185A (fr)
WO (1) WO2020176797A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013661A (es) 2020-05-01 2022-11-30 Nykode Therapeutics ASA Vacuna y uso de la misma en la profilaxis y terapia de betacoronavirus.
JP2024511139A (ja) 2021-03-26 2024-03-12 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 癌を治療するための治療的組み合わせ
WO2022233851A1 (fr) 2021-05-03 2022-11-10 Nykode Therapeutics ASA Constructions immunogènes et vaccins destinés à être utilisés dans le traitement prophylactique et thérapeutique de maladies infectieuses
WO2022238363A1 (fr) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Constructions immunogènes et vaccins destinés à être utilisés dans le traitement prophylactique et thérapeutique de maladies infectieuses
EP4337247A1 (fr) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Constructions induisant une tolérance et compositions et leur utilisation pour le traitement de troubles immunitaires
EP4337248A2 (fr) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Co-expression de constructions et de composés immunostimulants
IL308313A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Tolerance-inducing structures and preparations and their use for the treatment of immune disorders
AU2022272650A1 (en) 2021-05-10 2023-10-12 Nykode Therapeutics ASA Co-expression of constructs and immunoinhibitory compounds
WO2022238381A2 (fr) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Constructions d'immunothérapie pour le traitement d'une maladie
CA3235174A1 (fr) 2021-11-03 2023-05-11 Peter Ebert Constructions immunogenes et vaccins destines a etre utilises dans le traitement prophylactique et therapeutique de maladies provoquees par le sars-cov-2
WO2024092025A1 (fr) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructions et leur utilisation
WO2024100196A1 (fr) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression de constructions et de polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216403A1 (en) * 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2018089669A2 (fr) * 2016-11-10 2018-05-17 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201708536A (zh) * 2015-05-26 2017-03-01 艾法西斯公司 個人化的基於遞送載體之免疫療法及其用途
WO2017118695A1 (fr) * 2016-01-08 2017-07-13 Vaccibody As Vaccin thérapeutique anticancéreux à néoépitope
IL299926A (en) * 2016-03-31 2023-03-01 Biontech Us Inc Neoantigens and methods for using them
SG11201901432YA (en) * 2016-08-25 2019-03-28 Nantomics Llc Immunotherapy markers and uses therefor
CN111065406A (zh) * 2017-06-21 2020-04-24 特兰斯吉恩股份有限公司 个性化疫苗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216403A1 (en) * 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2018089669A2 (fr) * 2016-11-10 2018-05-17 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELIZABETH I. BUCHBINDER ET AL: "CTLA-4 and PD-1 Pathways : Similarities, Differences, and Implications of Their Inhibition", AMERICAN JOURNAL OF CLINICAL ONCOLOGY (CANCER CLINICAL TRIALS)., vol. 39, no. 1, 1 February 2016 (2016-02-01), US, pages 98 - 106, XP055393184, ISSN: 0277-3732, DOI: 10.1097/COC.0000000000000239 *
See also references of WO2020176797A1 *
XUE WEI ET AL: "SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors", ONCOTARGET, vol. 7, no. 50, 13 December 2016 (2016-12-13), pages 83088 - 83100, XP093025668, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347755/pdf/oncotarget-07-83088.pdf> DOI: 10.18632/oncotarget.13070 *

Also Published As

Publication number Publication date
EP3930747A1 (fr) 2022-01-05
JP2022521792A (ja) 2022-04-12
WO2020176797A1 (fr) 2020-09-03
CN113631185A (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
EP3930747A4 (fr) Association d&#39;immunothérapies pour le traitement du cancer
EP3781564A4 (fr) Composés pour le traitement d&#39;un cancer
EP3678663A4 (fr) Polythérapie pour le traitement du cancer
EP3706770A4 (fr) Polyimmunothérapies pour le traitement du cancer
EP3892282A4 (fr) Association pour le traitement du cancer
GB201903546D0 (en) Cancer treatment
EP3836909A4 (fr) Biomarqueurs pour la cancérothérapie
IL285807A (en) Immunotherapy for cancer treatment
IL287907A (en) Cancer treatment methods
EP3946456A4 (fr) Immunothérapie anticancéreuse synergique ciblée
EP3820461A4 (fr) Méthode de traitement du cancer
EP3755711A4 (fr) Composition immunothérapeutique pour le traitement du cancer
EP3713576A4 (fr) Méthodes de traitement du cancer
SG11202010528XA (en) Combinations for treating cancer
IL287652A (en) Cancer treatment
EP4025204A4 (fr) Immunothérapie anticancéreuse
EP3990022A4 (fr) Anticorps anti-cd33 pour le traitement du cancer
EP3966208A4 (fr) Composés et méthodes de traitement du cancer
IL289006A (en) Combined immunotherapy for cancer
EP3755341A4 (fr) Polythérapies pour traiter des cancers
IL285466A (en) Cancer treatment
EP3962919A4 (fr) Composés pour traiter le cancer
EP3969012A4 (fr) Méthodes relatives à un traitement continu contre le cancer
EP3894561A4 (fr) Procédés de traitement du cancer
GB201909468D0 (en) Compounds for treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NYKODE THERAPEUTICS ASA

Owner name: NEKTAR THERAPEUTICS

A4 Supplementary search report drawn up and despatched

Effective date: 20230306

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230228BHEP

Ipc: C12N 7/00 20060101ALI20230228BHEP

Ipc: C07K 16/28 20060101ALI20230228BHEP

Ipc: A61K 39/00 20060101AFI20230228BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231003